Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.73 -5.9%	$0.77	$0.38 ▼ $115.57	$8.52M	0.71	1.58 million shs	55,781 shs
EVOK Evoke Pharma	$5.45 +3.0%	$4.52	$1.94 ▼ $12.32	$8.50M	-0.04	952,678 shs	44,930 shs
RNAZ TransCode Therapeutics	$9.73 -1.5%	$9.83	$6.15 ▼ $739.20	$8.08M	1.46	188,519 shs	10,422 shs
SPRC SciSparc	$2.46 -18.8%	$6.10	$2.43 ▼ $37.59	$1.30M	0.88	264,254 shs	604,924 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	+1.01%	+12.72%	-0.03%	+35.03%	-98.87%
EVOK Evoke Pharma	-3.64%	-16.56%	+33.92%	+57.63%	+20.34%
RNAZ TransCode Therapeutics	-1.69%	+4.88%	-15.99%	+49.02%	-99.89%
SPRC SciSparc	-28.87%	-28.37%	-54.71%	-54.53%	-65.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Earnings & Valuation
AEON AEON Biopharma	2.9668 of 5 stars	3.5	5.0	0.6	1.9
EVOK Evoke Pharma	0.6964 of 5 stars	0.0	5.0	2.6	0.0
RNAZ TransCode Therapeutics	1.9844 of 5 stars	3.5	2.0	2.7	0.6
SPRC SciSparc	1.0438 of 5 stars	0.0	5.0	2.6	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	49,013.23% Upside
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,819.71% Upside
SPRC SciSparc	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
EVOK Evoke Pharma	$10.25M	0.83	N/A	N/A	$2.81 per share	1.95
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$7.37 per share	N/A
SPRC SciSparc	$1.31M	0.99	N/A	N/A	$18.13 per share	0.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$6.08	4.07	N/A	N/A	N/A	N/A	-994.63%	N/A
EVOK Evoke Pharma	-$5.35M	-$2.56	N/A	∞	N/A	-42.07%	-99.48%	-33.58%	11/5/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-378.30%	-186.01%	N/A
SPRC SciSparc	-$6.28M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SPRC, AEON, RNAZ, and EVOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	EVOK Evoke Pharma	-$0.30	-$0.62	-$0.32	-$0.62	$3.80 million	$3.75 million
8/14/2025	Q2 2025	RNAZ TransCode Therapeutics	-$8.68	-$4.94	+$3.74	-$5.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
EVOK Evoke Pharma	N/A	1.37	1.32
RNAZ TransCode Therapeutics	N/A	5.27	5.27
SPRC SciSparc	N/A	5.36	5.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
EVOK Evoke Pharma	N/A
RNAZ TransCode Therapeutics	N/A
SPRC SciSparc	25.06%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
EVOK Evoke Pharma	2.29%
RNAZ TransCode Therapeutics	0.01%
SPRC SciSparc	1.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.64 million	74.37 million	Not Optionable
EVOK Evoke Pharma	4	1.56 million	1.52 million	Not Optionable
RNAZ TransCode Therapeutics	9	830,000	834,000	Not Optionable
SPRC SciSparc	4	530,000	527,000	Not Optionable

SPRC, AEON, RNAZ, and EVOK Headlines

Recent News About These Companies

SciSparc Shareholders Approve Merger with AutoMax

August 28 at 4:31 PM | tipranks.com

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

August 28 at 9:24 AM | globenewswire.com

SciSparc Ltd. Shareholders Approve Merger with AutoMax Motors Ltd. to Expand into Automotive Sector

August 28 at 6:51 AM | quiverquant.comQ

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

August 28 at 6:45 AM | globenewswire.com

SciSparc Shareholders Approve Key Proposals at August Meeting

August 26 at 12:27 AM | msn.com

SciSparc (NASDAQ:SPRC) Stock Price Down 8.9% - Here's What Happened

August 26 at 2:30 AM | americanbankingnews.com

SciSparc Ltd. Reschedules Special Shareholder Meeting Due to Lack of Quorum

August 25, 2025 | tipranks.com

SciSparc Announces Patent Filing and Merger Updates

August 8, 2025 | theglobeandmail.com

SciSparc and Clearmind Publish Patent for Novel Obesity Therapy

August 8, 2025 | tipranks.com

SciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and Obesity

August 7, 2025 | quiverquant.comQ

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

August 7, 2025 | globenewswire.com

SciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 31, 2025 | finanznachrichten.de

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 30, 2025 | globenewswire.com

Clearmind Medicine files international patent application under PCT

July 30, 2025 | msn.com

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

July 30, 2025 | globenewswire.com

SciSparc Ltd. Regains Nasdaq Compliance

July 22, 2025 | tipranks.com

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

July 22, 2025 | globenewswire.com

SciSparc Announces 1-for-21 Reverse Share Split - Morningstar

June 26, 2025 | morningstar.comM

SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum

June 25, 2025 | msn.com

SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share Split

June 25, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC, AEON, RNAZ, and EVOK Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.73 -0.05 (-5.93%)

Closing price 03:59 PM Eastern

Extended Trading

$0.73 +0.00 (+0.04%)

As of 04:49 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Evoke Pharma NASDAQ:EVOK

$5.45 +0.16 (+3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$5.46 +0.01 (+0.28%)

As of 06:20 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

TransCode Therapeutics NASDAQ:RNAZ

$9.73 -0.15 (-1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$9.62 -0.11 (-1.13%)

As of 04:10 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

SciSparc NASDAQ:SPRC

$2.46 -0.57 (-18.81%)

Closing price 04:00 PM Eastern

Extended Trading

$2.48 +0.02 (+0.61%)

As of 06:25 PM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time